Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10531173 | 0.82 | ALDH1A1 (0.44) | KMT2AMEN1RAB9AALDH1A1KDM4E | |
| Bromide SCHEMBL10526748 | 0.82 | ALDH1A1 (0.54) | KMT2AMEN1RAB9AALDH1A1KDM4E | |
| SCHEMBL10531137 | 0.82 | KMT2A (0.47) | KMT2AMEN1ALDH1A1KDM4EPABPC1 | |
| Bromide SCHEMBL10531147 | 0.81 | ALDH1A1 (0.44) | KMT2AMEN1RAB9AALDH1A1KDM4E | |
| Bromide SCHEMBL10529155 | 0.81 | KMT2A (0.49) | KMT2ARAB9AALDH1A1KDM4EPABPC1 | |
| SCHEMBL10528532 | 0.78 | MAPT (0.49) | KMT2ARAB9AALDH1A1KDM4EGLA | |
| SCHEMBL765905 | 0.77 | KDM4E (0.76) | KMT2AMEN1RAB9AALDH1A1KDM4E | |
| Bromide SCHEMBL10526754 | 0.77 | MAPT (0.51) | RAB9AALDH1A1KDM4EGLASMN1; SMN2 | |
| SCHEMBL10526705 | 0.76 | KMT2A (0.43) | KMT2AMEN1RAB9AALDH1A1KDM4E | |
| Ammonia Solution, Strong SCHEMBL28760030 | 0.76 | KDM4E (0.73) | KMT2AMEN1RAB9AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090041740-A1 | CANCER TREATMENT BY METABOLIC MODULATIONS | ENGENE, INC. (CA) | 2009-02-12 | — | — | US | disclosed |
| US-20070249484-A1 | Process for the Photoactivation and use of a Catalyst by an Inverted Two-Stage Procedure | CIBA SPECIALTY CHEMICALS CORP. | 2007-10-25 | — | — | US | disclosed |
| US-20050202559-A1 | Cancer treatment by metabolic modulations | HERCULES CAPITAL, INC. | 2005-09-15 | — | — | US | disclosed |
| EP-1556088-A2 | COMPOSITIONS FOR CANCER TREATMENT | Engene, Inc. (CA) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004039412-A2 | COMPOSITIONS FOR CANCER TREATMENT | ENGENE, INC. (CA) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249484-A1 | Process for the Photoactivation and use of a Catalyst by an Inverted Two-Stage Procedure | INF2, CRY2, CCNT2 | KMT2A 89/4885MEN1 2611/4885RAB9A 3024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.